Polydatin / Resveratrol Comparison

On the surface, they look like near-identical options — polydatin converts to resveratrol in the body, so why not just take resveratrol directly? The answer comes down to several meaningful biological and pharmacokinetic differences that make polydatin worth considering in its own right, not simply as a resveratrol precursor.

1. Polydatin is more water-soluble and more stable
Resveratrol is notoriously poorly water-soluble and chemically unstable — it degrades rapidly when exposed to light, heat, and oxygen, and its oral bioavailability in standard form is very low (estimated at under 1% reaching systemic circulation as intact resveratrol). Polydatin, as the glucoside form, is significantly more water-soluble and more chemically stable in the gut environment. Adding pro-liposomal delivery to an already more stable molecule compounds the bioavailability advantage.

2. Polydatin has its own direct biological activity — it is not just a prodrug
This is the most important distinction. Polydatin has been shown to exert direct anticancer effects in its intact glucoside form, before conversion occurs:

• Direct G6PD inhibition — the PPP-disrupting effect was demonstrated with polydatin itself, not resveratrol

• Direct induction of ER stress and ROS accumulation in cancer cells

• A distinct receptor and transporter binding profile — polydatin's glucose moiety allows interaction with glucose transporters (GLUTs), which are overexpressed on many cancer cells, potentially facilitating preferential uptake into high-glucose-consuming tumour cells in a way resveratrol cannot replicate

3. The conversion to resveratrol is a bonus, not the whole story
When polydatin is absorbed and converted to resveratrol, the person effectively gets both molecules active in the body simultaneously — polydatin acting directly in the gut lumen and during early absorption, and resveratrol acting systemically after conversion. Taking resveratrol directly gives only the back half of this picture.

4. The G6PD inhibition research currently sits with polydatin, not resveratrol
The research specifically demonstrating direct inhibition of the G6PD enzyme was conducted using polydatin. Someone choosing a compound specifically for this mechanism has stronger evidence to favour polydatin over resveratrol.

Where liposomal resveratrol still has a role:
Standard and liposomal resveratrol have a larger body of human clinical trial data behind them, and some practitioners prefer it for systemic anti-inflammatory and sirtuin-activating, where the resveratrol molecule specifically has supporting evidence.

Practical Summary Table

References

• Polydatin is better than resveratrol in anti-inflammatory activity: role of sirtuin-1? https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2022.857879/full

• Comparative pharmacokinetics and tissue distribution of polydatin and its metabolite resveratrol following oral administration https://www.sciencedirect.com/science/article/abs/pii/S0378874123008784

• A new inhibitor of glucose-6-phosphate dehydrogenase blocks the pentose phosphate pathway and suppresses malignant proliferation and metastasis in vivo https://pmc.ncbi.nlm.nih.gov/articles/PMC5951921/